title: Potential contribution of matrix metalloproteinase-9 (mmp-9) to cerebral vasospasm after experimental subarachnoid hemorrhage in rats.
abstract: This study investigated the possible involvement of matrix metalloproteinase 9 (MMP-9) in cerebral vasospasm (CVS) after subarachnoid hemorrhage (SAH) in rats. The CVS model was established by injection of fresh autologous nonheparinized arterial blood into the cisterna magna. Experiment 1 aimed to investigate the timecourse of the MMP-9 expression in the basilar artery after SAH. In Experiment 2, we chose the maximum time point of vasospasm (Day 3) and assessed the effect of SB-3CT (a selective MMP- 9 inhibitor) on the regulation of cerebral vasospasm. The cross-sectional area of basilar artery was measured by H&E staining and the MMP-9 expression was assessed by immunohistochemistry analysis. The elevated expression of MMP-9 was detected in the basilar artery after SAH and peaked on day 3. After intracisternal administration of SB-3CT, the vasospasm was markedly attenuated after blood injection on day 3. Our results suggest that MMP-9 is increasingly expressed in a parallel time course to the development of cerebral vasospasm in this rat experimental model of SAH and that the administration of the specific MMP-9 inhibitor could prevent or reduce cerebral vasospasm caused by SAH.
authors.affiliation: Suzhou, P.R.China.
authors.forename: Zhong
authors.initials: Z
authors.lastname: Wang
authors.forename: Qi
authors.initials: Q
authors.lastname: Fang
authors.forename: Bao-Qi
authors.initials: BQ
authors.lastname: Dang
authors.forename: Xu-Ming
authors.initials: XM
authors.lastname: Shen
authors.forename: Zhang
authors.initials: Z
authors.lastname: Shu
authors.forename: Gang
authors.initials: G
authors.lastname: Zuo
authors.forename: Wei-Chun
authors.initials: WC
authors.lastname: He
authors.forename: Gang
authors.initials: G
authors.lastname: Chen
mesh_terms: D000818:Animals; D001488:Basilar Artery / Q000187:drug effects / Q000201:enzymology / Q000473:pathology; D006573:Heterocyclic Compounds, 1-Ring / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D007150:Immunohistochemistry; D008297:Male; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013345:Subarachnoid Hemorrhage / Q000150:complications* / Q000188:drug therapy / Q000201:enzymology*; D013450:Sulfones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D020301:Vasospasm, Intracranial / Q000150:complications* / Q000188:drug therapy / Q000201:enzymology*
chemical_list: D006573:Heterocyclic Compounds, 1-Ring; C429533:SB 3CT compound; D013450:Sulfones; D020780:Matrix Metalloproteinase 9; C572337:Mmp9 protein, rat